Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for Aardvark Therapeutics in a research note issued on Thursday, May 15th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings per share of ($2.46) for the year, up from their previous estimate of ($2.49). Cantor Fitzgerald currently has a "Overweight" rating and a $50.00 price objective on the stock.
Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.01).
Several other research analysts also recently commented on AARD. Royal Bank of Canada decreased their target price on shares of Aardvark Therapeutics from $21.00 to $20.00 and set an "outperform" rating on the stock in a research note on Thursday. Bank of America lifted their target price on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the stock a "buy" rating in a research note on Thursday, March 27th. Finally, Morgan Stanley initiated coverage on shares of Aardvark Therapeutics in a research note on Monday, March 10th. They issued an "overweight" rating and a $29.00 target price on the stock.
Get Our Latest Stock Analysis on Aardvark Therapeutics
Aardvark Therapeutics Trading Up 8.8%
AARD stock opened at $9.89 on Monday. Aardvark Therapeutics has a one year low of $4.88 and a one year high of $19.58. The business's 50 day simple moving average is $9.04.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the stock. Decheng Capital LLC purchased a new position in Aardvark Therapeutics during the 1st quarter valued at $29,419,000. Cormorant Asset Management LP purchased a new position in Aardvark Therapeutics during the 1st quarter valued at $6,009,000. Braidwell LP purchased a new position in Aardvark Therapeutics during the 1st quarter valued at $3,755,000. Adage Capital Partners GP L.L.C. purchased a new position in Aardvark Therapeutics during the 1st quarter valued at $1,878,000. Finally, Goldman Sachs Group Inc. purchased a new position in Aardvark Therapeutics during the 1st quarter valued at $153,000.
Aardvark Therapeutics Company Profile
(
Get Free Report)
Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aardvark Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aardvark Therapeutics wasn't on the list.
While Aardvark Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
